Jaguar Health Expands Compassionate Use of Crofelemer in Infant with MVID

Jaguar Health, Inc. announced the provision of its innovative crofelemer powder for oral solution to treat intestinal failure (IF) in an infant with microvillus inclusion disease (MVID) in the European Union. This comes under compassionate use, expanding accessibility beyond the current patient eligibility for their trials.

The company's efforts focus on global development of crofelemer as adjunctive therapy to parenteral support (PS) for treating rare IF diseases, with MVID and short bowel syndrome included. Recent data presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition Meeting showed notable reductions in PS requirements in patients using crofelemer, highlighting its potential in IF management.

Jaguar Health remains committed to progressing its international development program for addressing rare disorders and plans to apply for Breakthrough Therapy Designation in 2027. Research shows crofelemer helps reduce the need for PS, crucial for pediatric patients with lifelong PS dependence.